Oxford Biomedica
https://oxb.comStrasbourg, 67400
France
Categories
About Oxford Biomedica:
Oxford Biomedica is a cell and gene therapy company with a core position in lentiviral vector research and bioprocessing. Oxford Biomedica is an innovative leading viral vector specialist focused on delivering life changing therapies to patients. Cell and gene therapy is the treatment of disease by the delivery of therapeutic genetic material (DNA or RNA), into a patient’s cells. One highly effective approach to delivering the genetic information is to re-engineer existing viruses to be safe del...elivery vehicles (vectors) to insert the genetic material into patients cells. This can be achieved either by directly administering the vector to the patient (often referred to as in vivo gene therapy), or by first introducing the genetic material to cells or tissue outside of the body, before administering the cells or tissue into the patient (often referred to as ex vivo gene therapy, or gene-modified cell therapy).
Oxford Biomedica works across key viral vector delivery systems including those based on lentivirus, adeno-associated virus (AAV) and adenovirus, providing innovative solutions to cell and gene therapy biotechnology and biopharma companies for their process development, analytical development and manufacturing needs. Oxford Biomedica plc (the Company) and its subsidiaries (together Oxford Biomedica or the Group) have built a sector leading lentiviral vector delivery system, LentiVector® platform, which the Group leverages to develop product candidates in-house, before seeking partners to take the products into clinical trials.
Oxford Biomedica UK Limited (OXB) is based across several locations in Oxfordshire, UK. In early 2022, the Group established Oxford Biomedica Solutions, a new US based subsidiary AAV manufacturing and innovation business, based near Boston, US.
Service Offerings:
- Commercially approved vectors
- Process Development
- SecNuc
- Tripsystem
- Lentiviral vectors
- Process Analytics
- Early clinical and commercial manufacturing capabilities